Abstract RAS and BRAF proteins are frequently mutated in colorectal cancer (CRC) and have been associated with therapy resistance in metastatic CRC patients. RAS isoforms are considered to act as redundant entities in physiological and pathological settings. However, there is compelling evidence that mutant variants of RAS and BRAF […]
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.
